Blue Jet Healthcare Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vg50i33c3zgqwksng9rvzq7s.pdf

Key Takeaways


Pharma Intermediates: The Growth Story

VK Singh: "I think the molecule is very well poised to be a blockbuster."

Contrast Media: Delayed, Not Derailed

Ganesh Karuppannan: "What you should be actually like looking at is more on the product launches and the opportunities what we have on each of these molecules."

Capacity Build-Out: Capex on Track


R&D & New Capabilities

VK Singh: "One is that whenever there is a chemistry where there is chiral selection involved, then the enzymatic process is significantly more effective than a regular chemical synthesis process."

Margins & Mix


Guidance & Commitments

CommitmentSpecificsTimeline
Contrast media demand stabilizationDemand for customers to stabilizeFrom Q4 2025 onwards
Contrast media volume recoveryCome closer to last year’s volume numbersFY25 (implied H2 catch-up)
Iodinated product scale-upScale up after successful validationQ4 FY25
Unit 2 new capacity utilizationReach optimal utilizationQ3 and Q4 FY25
Unit 3 Mahad commissioningBackward-integration capacity for contrast mediaQ1 FY26
Small-volume plant commissioningReady for proof-of-concept, regulatory filings, clinical-trial suppliesQ1 FY26
Pharma intermediate rampRamp to customers’ expectations on the cardiovascular moleculeNext two quarters
Capex~₹200 crores annual plan maintainedOngoing

Key Metrics

MetricQ2 FY25
Revenue₹207.1 cr, +28% QoQ and +18% YoY
Gross margin57%, +2 ppt QoQ, flat YoY
EBITDA₹69.5 cr, +57% QoQ and +11% YoY
EBITDA margin33.6% (per an analyst's math), vs ~30% blended in H1
PAT₹58.3 cr, +54% QoQ and +22% YoY, highest ever quarterly net profit
PAT margin28% of total revenues
H1 FY25 revenue₹371.1 cr, +3% YoY
H1 FY25 EBITDA₹113.7 cr, -6.4% YoY
H1 FY25 PAT₹96.1 cr, +4.5% YoY
Contrast media revenue (Q2)+76% QoQ, -11% YoY
Contrast media revenue (H1)₹177.9 cr, -31% YoY
Pharma intermediate revenue (H1)₹119.8 cr, +282% YoY
Cash and treasury investments₹323.3 cr as of Sep 2024, debt-free
Dividend paid₹1 per share, total ₹17.35 cr, first ever payout
Capex guidance₹200 cr annually, base case, on track
Unit 2 new capacity120 KL added at cost of ₹90 cr, commercial supplies commenced mid-Sep
Incremental capacity commissioning80 KL in same block, validation ongoing, commercial supplies expected Q3 onward
Revenue impact of goods-in-transit shift~₹60–70 cr shifted from Q1 to Q2
Transit time (contrast media)55–60 days, up from 30–35 days pre-Red Sea crisis